The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

Fatigue, best described as an overwhelming feeling of tiredness and exhaustion, occurs in
the context of various neurological diseases. The high prevalence of fatigue as either a …

Background Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …

Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The
increasing availability of effective disease-modifying therapies has shifted the aim of …

The treatment of multiple sclerosis (MS) has changed over the last 20 years. All
immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a …

Background and purpose There is still no curative treatment for multiple sclerosis (MS), but
during the last 20 years eight different disease‐modifying compounds have been approved …

Background Multiple sclerosis (MS) is a chronic and autoimmune disease of the central
nervous system (CNS), mainly characterized by inflammatory demyelination, which …

Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system
determined by a presumed autoimmune process mainly directed against myelin …

Background: The Association of British Neurologists (ABN) 2015 guidelines suggested
classifying multiple sclerosis therapies according to their average relapse reduction. We …